set reason episod beatabl mid-term financi
expect consist busi segment capabl in-
line avail oper margin lever top-lin guidanc appear set
conserv side manag seem reinvigor
commit reliabl return irrespect moder currenc
headwind convers improv told believ
articul profil worthi market multipl in-lin pt
financi expect reason room upsid set
plan period top bottom line expect respect
trend line total return low doubl digit dividend
figur dividend pay-out target
top-lin minimum compani clearli leav room
unforeseen event cvg expect grow mitg rtg
diabet least low doubl digit ceo omar ishrak messag
strong commit therapi innov key underpin top-lin
growth well receiv investor
cfo karen parkhil articul adjust ep minimum commit
abl withstand moder fx headwind compani plan
allow fx tailwind drop bottom line ep leverag larg
stem op-margin improv bp per year opportunist
covidien allow increas flexibl manag seem deadli
seriou improv convers next year
around elev around
term perform incent senior manag alter
weight toward sharehold valu creation shorter term
incent explicit compon free cash flow gener
told believ expect set plausibl compani
mdt capabl size leav room episod upsid believ
financi profil worthi market multipl islin
target price rel ep estim
cvg growth profil cvg success migrat tradit
slow growth market growth fy fy come
faster grow market tavr af endovenous/dcb implant
diagnost lvad contribut mitral renal denerv
late plan period continu pg
tr target
intrins slower grow segment get boost leadless devic pacer
defib well tyrx risk share sit hand regard tavr product
iter horizon aortic platform line design specif younger patient lower
profil better access coronari even position better ensur maximum
annular diamet freedom heavi calcium interact intrepid tmvr devic proceed
apac screen rule-out base anatom diseas sever
criteria suggest promis rel generaliz solut trans-femor implant
becom avail fih late fiscal year clearli bias complet elimin
regurgit afford mitral replac rather repair also found interest
avidli pursu wider rang af ablat cathet inclus arctic line new puls field
modal could provid durabl safer ablat
rtg inclus spine enabl growth profil core spine hardwar market like
remain challeng agre appropri view busi
holist inclus enabl technolog navig robot overal msd expect
brain therapi led neurovascular grow strong doubl digit enjoy low
doubl digit market growth overal db like rough coupl year new competit
boston scientif buy nr mdt competit respons
direct stimul close loop system help stem tide toward end
plan period sacral nerv stimul specialti therapi along ent cmf also like
pressur mid-term new gener platform wont appear fy
offset sacral nerv specialti therapi probabl typic mid-to high singl digit
perform cmf ent peg collect pain market inclus minim
invas spine grow high singl digit expect continu mid high teen growth
rate mdt franchis believ altern sub-percept frequenc
work equal well waveform option way go
diabet sustain dd growth feel diabet franchis well posit
close loop system continu gain momentum pump market compound-annual-growth-rate
given tighter glycem control lower patient burden afford dispos revenu per patient
goe per year migrat standard sensor consum close loop pump
also feel mdt stand-alone cgm strategi sound market grow dont
disbeliev go share plan period believ
import subset incent mdi patient unwil migrat pump therapi
attract predict alert afford mdt ai enabl cgm oppos no-fuss muss
mitg growth key theme divis continu migrat open minim
invas surgeri either enabl tradit laparoscop robot technolog
disappoint robot platform like remain beta test phase
fiscal year appear thought embodi regard cost
accommod surgeon prefer advanc energi stapl franchis appear
long mid-singl digit trajectori front promis initi underway
page
intervent lung gynecolog health gi diseas pill-cam colon cancer screen esophag
ablat liver tumor ablat em dialysi base respiratori busi may exceed low
sd growth dont believ target mitg unfeas
thesi valuat risk continu see upsid share price given view
like enjoy organ msd sale growth compound-annual-growth-rate modest margin expansion/shar
buyback drive hsd ep growth compound-annual-growth-rate pt base rel valuat
framework regress forward top-lin compound-annual-growth-rate rel forward price-to-earnings med-tech stock
analysi suggest rel forward multipl slightli less
forward multipl enjoy last month month price target invok
forward multipl estim ep month henc given increas cash
access accru recent enact us tax reform hope
aggress vis-a-vi high growth earlier stage acquisit could add spice stori given
mdt unquestion strength clinic trial regulatori commerci execut compani
explicit commit margin expans unfett access futur
global cash encourag us elimin discount regress suggest rel price-to-earnings
previous appli target price risk pt
opacity/volatil greater expect matur product market weak failur meet margin
page
page
period million ens ens net incom ex ni ex attribut analysisgross margin excl margin incl margin excl margin attribut analysi y/i cc pf pmr incom attribut medtron plc
world largest medic devic compani leadership across major market
compani four busi segment cardiac vascular minim invas technolog
restor therapi diabet headquart dublin ireland
continu see upsid share price given view like enjoy organ
msd sale growth compound-annual-growth-rate modest margin expansion/shar buyback drive hsd
ep growth compound-annual-growth-rate given increas cash access accru recent
enact us tax reform hope aggress vis-a-vi high growth earlier
stage acquisit could add spice stori given mdt unquestion strength clinic
trial regulatori commerci execut
valuat risk
pt base rel valuat framework regress forward top-lin compound-annual-growth-rate
rel forward price-to-earnings med-tech stock analysi suggest rel forward multipl
slightli less forward multipl enjoy last
month price target invok forward multipl estim ep
month henc compani explicit commit margin expans
unfett access futur global cash encourag us elimin discount
regress suggest rel price-to-earnings previous appli target price risk pt
includ emerg market opacity/volatil greater expect matur product market weak
failur meet margin expans expect
compani mention note
bruce nudel herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express specif
recommend report
